menu
    • menu
    [{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"Sanaria","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atovaquone","moa":"Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ Sanaria","highestDevelopmentStatusID":"6","companyTruncated":"University Hospital T\u00fcbingen \/ Sanaria"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Richmond Pharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atovaquone","moa":"Cytochrome b","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicines for Malaria Venture \/ Richmond Pharmacology","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ Richmond Pharmacology"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Richmond Pharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Atovaquone","moa":"Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines for Malaria Venture \/ Richmond Pharmacology","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ Richmond Pharmacology"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Atovaquone","moa":"Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quotient Sciences \/ Fresenius Kabi AG","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atovaquone","moa":"Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Translational Genomics Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atovaquone","moa":"||Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Translational Genomics Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Genomics Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Translational Genomics Research Institute \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Mepron

    Menu

    Mepron

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quotient Sciences

                            United Kingdom
                            Bio-Europe
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Fresenius Kabi AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quotient Doses Volunteers in Malaria Venture’s Long-Acting Injectable Prevention Study

                            Details : MMV371 is a prodrug of atovaquone (selective inhibitor of cytochrome bc1 complex), ben investigated for malaria in adults.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 28, 2024

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Fresenius Kabi AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medicines for Malaria Venture

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Medicines for Malaria Venture

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Richmond Pharmacology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atoguanil BA Study

                            Details : Atovaquone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 30, 2021

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Richmond Pharmacology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Translational Genomics Research Institute

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Translational Genomics Research Institute

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atovaquone,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGen and HonorHealth trial atovaquone plus azithromycin for Covid-19

                            Details : Atovaquone plus azithromycin combination was studied in other infectious disease and is expected to offer a well-tolerated option for patients infected with the novel coronavirus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2020

                            Lead Product(s) : Atovaquone,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medicines for Malaria Venture

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Medicines for Malaria Venture

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Richmond Pharmacology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

                            Details : Atovaquone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2019

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Richmond Pharmacology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University Hospital Tübingen

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University Hospital Tübingen

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Sanaria

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis

                            Details : Atovaquone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 08, 2016

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Sanaria

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension

                            Details : Atovaquone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 21, 2013

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth